Latest Content

AI chatbots reshape therapy, pushing clinicians to unite around common change principles and connection.

Study links schizophrenia’s earlier onset to higher genomic deletion CNV burden, showing future potential for personalized care.

Round on the latest news in psychiatry from the last week.

Adial seeks FDA priority voucher to speed AD04 review, a biomarker-guided therapy aiming to curb heavy drinking in alcohol use disorder.

FDA expands Caplyta label to prevent schizophrenia relapse, cutting risk 63% and showing weight-neutral tolerability for sustained long-term stability.

FDA accelerates psychedelic drug development to advance agents for TRD, PTSD, and AUD.

Explore GLP-1 agonists and their "truly transformative" role in psychiatry in this podcast.

In this CME article, learn how depression hides in organ failure, transplants, neurologic disease, and hormonal shifts—plus screening tips and safer treatment choices.

AXS-05 for Alzheimer disease agitation nears FDA decision date.

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.

AFSP and JED plan a 2026 merger to form the largest US suicide prevention nonprofit, uniting research, youth mental health programs, advocacy, and community support.

Learn how antipsychotics and stress raise prolactin, what symptoms to spot, and when to test—plus practical options to lower levels.

Psychedelic therapies surge, but a rushed FDA shortcut risks safety; learn why ibogaine claims need rigorous trials and oversight.